Med-Life Discoveries

Med-Life Discoveries Med-Life Discoveries is a Canadian BioPharma company developing plasmalogen replacement therapies.

MLD has spent their time in Amsterdam at World Orphan Drug Congress Europe spreading awareness of RCDP and our PPI-1011 ...
10/29/2025

MLD has spent their time in Amsterdam at World Orphan Drug Congress Europe spreading awareness of RCDP and our PPI-1011 program, as well as highlighting the importance of the patients’ voice in drug development for an ultra rare disease.

MLD is excited to be presenting a poster and two talks on our RCDP program at the World Orphan Drug Congress in Amsterda...
10/20/2025

MLD is excited to be presenting a poster and two talks on our RCDP program at the World Orphan Drug Congress in Amsterdam next week.

MLD is excited to announce that it will be attending World Orphan Drug Congress (WODC) Europe in Amsterdam from October 27-29th. WODC Europe is the leading conference in Europe on the development of drugs for orphan diseases. The small patient populations in these orphan diseases means that the trad

The influence that the type of bond in ether lipids has on their transport within a cell is the topic of this month's li...
10/09/2025

The influence that the type of bond in ether lipids has on their transport within a cell is the topic of this month's literature blog.

Böhlig K, Iglesias-Artola JM, Asaro A, Lennartz HM, Link AC, Drobot B, and Nadler A. (2025) Bifunctional probes reveal the rules of intracellular ether lipid transport. Angewandte Chemie

This month the literature blog is discussing an interesting paper that evaluates the relationship between plasmalogens a...
09/11/2025

This month the literature blog is discussing an interesting paper that evaluates the relationship between plasmalogens and L-DOPA-induced dyskinesia.

Kaya I, Vallianatou T, Nilsson A, Bjäterot P, Shariatgorji R, Svenningsson P, Bezard E, and Andren PE. (2025) Brain-region-specific lipid dysregulation in L-DOPA-induced dyskinesia in a primate model of Parkinson’s disease. Parkinson’s Disease Parkinson’s disease (PD) is a progressive neurode...

Dr. Tara Smith laying out the future plans for plasmalogen therapy in RCDP and the RhizoKids International conference
07/24/2025

Dr. Tara Smith laying out the future plans for plasmalogen therapy in RCDP and the RhizoKids International conference

Shawn Ritchie gave a great presentation this morning at the RhizoKids International conference talking about the basics ...
07/24/2025

Shawn Ritchie gave a great presentation this morning at the RhizoKids International conference talking about the basics of plasmalogens and how these special lipids underlie the RCDP disease process.

MLD is thrilled to be back to Children’s Harbor for Rhizokids International 2025 Family Conference.
07/22/2025

MLD is thrilled to be back to Children’s Harbor for Rhizokids International 2025 Family Conference.

Address

407-15 Innovation Boulevard
Saskatoon, SK
S7N2X8

Telephone

+13062448233

Website

Alerts

Be the first to know and let us send you an email when Med-Life Discoveries posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Med-Life Discoveries:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

Med-Life Discoveries LP

Med-Life Discoveries (MLD) is a biopharmaceutical and diagnostics company in Saskatoon, SK. Canada. We are developing plasmalogen replacement therapeutics for the treatment of several conditions including Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and a rare pediatric disease called Rhizomelic Chondrodysplasia Punctata (RCDP).

We are also the global manufacturer of the Cologic(TM) test for colorectal cancer risk and PanaSee (TM) test for pancreatic cancer risk. These products test for a metabolic deficiency associated with the establishment of the disease. We are currently working on therapeutic strategies to treat these metabolic deficiencies in effort to delay or prevent onset of these cancers.